Loading...
•
Sep 30, 2021
Guardant Health Q3 2021 Earnings Report
Guardant Health's revenue increased by 27% year-over-year, driven by growth in clinical and biopharma test volumes.
Key Takeaways
Guardant Health reported a 27% increase in revenue for the third quarter of 2021, reaching $94.8 million. The company saw significant growth in clinical and biopharma test volumes, despite the continued impact of COVID-19. However, the net loss also increased to $107.5 million, or $1.06 per share.
Revenue reached $94.8 million, a 27% increase compared to the third quarter of 2020.
Clinical tests increased by 35% year-over-year, with 22,806 tests reported.
Biopharmaceutical tests increased by 58% year-over-year, with 4,839 tests reported.
ORACLE study initiated to evaluate Guardant Reveal™ for predicting recurrence across eleven early-stage cancers.
Revenue by Segment
Forward Guidance
Guardant Health expects full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020.
Positive Outlook
- Full year 2021 revenue expected to be in the range of $360 million to $370 million.
- Revenue growth of 26% to 29% expected over full year 2020.
- Expansion of product portfolio with focus on early-stage cancer detection.
- Continued progress in developing blood-based cancer screening tests.
- Focus on improving patient clinical outcomes and lowering healthcare costs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...